CSPC Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

CSPC Pharmaceutical Group Ltd (1093.HK)

Q3 20262 Jul – 20 Aug 2026

▲4

CSPC's $1.77B AstraZeneca deal and sector tailwinds drive gains

AstraZeneca kidney therapy deal worth up to $1.77B CSPC signed a partnership with AstraZeneca potentially worth $1.77B, including $30M upfront and up to $1.74B in milestones. This validates CSPC's drug platform and brings cash, boosting investor confidence and the stock price.
This is the major new deal directly driving CSPC's outlook and price.
Innovative drug sector rebounds, out-licensing trend strong The innovative drug sector rebounded, with China's out-licensing deals nearing $100B in H1 2026. CSPC's deal is cited as a landmark, signaling strong demand for its technology platforms and supporting higher valuations.
Sector momentum and CSPC's role in the out-licensing trend lift sentiment and demand for the stock.
Pharma sector split: innovative drugs outperform While the broad pharma sector fell 13.6% in H1, innovative drugs bucked the trend. CSPC's $18.5B AstraZeneca deal (total value) highlights its leadership, attracting investors shifting from traditional to innovative pharma.
Shows CSPC benefiting from the rotation into innovative drugs, a key driver of its relative strength.
Moderna cancer vaccine success lifts innovative drug stocks Positive Phase III results for Moderna/Merck's cancer vaccine sent innovative drug stocks surging. CSPC Innovation rose over 10%, as the sector's triple earnings inflection point (commercialization, overseas deals, CXO boom) boosts optimism.
Sector-wide rally on positive clinical news lifts CSPC's stock, reflecting broader demand for innovative drugs.

July 20262 Jul – 20 Aug 2026

▲4

CSPC's $1.77B AstraZeneca deal and sector tailwinds drive gains

AstraZeneca kidney therapy deal worth up to $1.77B CSPC signed a partnership with AstraZeneca potentially worth $1.77B, including $30M upfront and up to $1.74B in milestones. This validates CSPC's drug platform and brings cash, boosting investor confidence and the stock price.
This is the major new deal directly driving CSPC's outlook and price.
Innovative drug sector rebounds, out-licensing trend strong The innovative drug sector rebounded, with China's out-licensing deals nearing $100B in H1 2026. CSPC's deal is cited as a landmark, signaling strong demand for its technology platforms and supporting higher valuations.
Sector momentum and CSPC's role in the out-licensing trend lift sentiment and demand for the stock.
Pharma sector split: innovative drugs outperform While the broad pharma sector fell 13.6% in H1, innovative drugs bucked the trend. CSPC's $18.5B AstraZeneca deal (total value) highlights its leadership, attracting investors shifting from traditional to innovative pharma.
Shows CSPC benefiting from the rotation into innovative drugs, a key driver of its relative strength.
Moderna cancer vaccine success lifts innovative drug stocks Positive Phase III results for Moderna/Merck's cancer vaccine sent innovative drug stocks surging. CSPC Innovation rose over 10%, as the sector's triple earnings inflection point (commercialization, overseas deals, CXO boom) boosts optimism.
Sector-wide rally on positive clinical news lifts CSPC's stock, reflecting broader demand for innovative drugs.

Latest2 Jul – 20 Aug 2026

▲4

CSPC's $1.77B AstraZeneca deal and sector tailwinds drive gains

AstraZeneca kidney therapy deal worth up to $1.77B CSPC signed a partnership with AstraZeneca potentially worth $1.77B, including $30M upfront and up to $1.74B in milestones. This validates CSPC's drug platform and brings cash, boosting investor confidence and the stock price.
This is the major new deal directly driving CSPC's outlook and price.
Innovative drug sector rebounds, out-licensing trend strong The innovative drug sector rebounded, with China's out-licensing deals nearing $100B in H1 2026. CSPC's deal is cited as a landmark, signaling strong demand for its technology platforms and supporting higher valuations.
Sector momentum and CSPC's role in the out-licensing trend lift sentiment and demand for the stock.
Pharma sector split: innovative drugs outperform While the broad pharma sector fell 13.6% in H1, innovative drugs bucked the trend. CSPC's $18.5B AstraZeneca deal (total value) highlights its leadership, attracting investors shifting from traditional to innovative pharma.
Shows CSPC benefiting from the rotation into innovative drugs, a key driver of its relative strength.
Moderna cancer vaccine success lifts innovative drug stocks Positive Phase III results for Moderna/Merck's cancer vaccine sent innovative drug stocks surging. CSPC Innovation rose over 10%, as the sector's triple earnings inflection point (commercialization, overseas deals, CXO boom) boosts optimism.
Sector-wide rally on positive clinical news lifts CSPC's stock, reflecting broader demand for innovative drugs.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.